hVIVO Partners with Inhalon Biopharma for Innovative RSV Treatment Trial

Open Orphan Plc ( (GB:HVO) ) just unveiled an update.

hVIVO plc has signed a contract with Inhalon Biopharma to conduct a Phase 2a human challenge trial for IN-002, an inhaled antiviral candidate for RSV infection. The trial, set to begin in the second half of 2026, will test the safety and efficacy of IN-002 at three dosing levels, potentially paving the way for a home-based treatment approach. This collaboration not only strengthens hVIVO’s order book but also highlights the increasing demand for novel therapeutics targeting respiratory diseases, particularly in vulnerable populations. The partnership underscores the importance of innovative drug delivery systems, aiming to provide effective and comfortable treatment options for RSV and similar infections.

More about Open Orphan Plc

hVIVO plc is a fast-growing specialist contract research organisation (CRO) that leads in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The company provides comprehensive early clinical development services to a broad client base, including top global biopharma companies. It boasts a portfolio of 11 human challenge models and offers services through its Venn Life Sciences and hLAB brands, with extensive capabilities in virology, immunology, and molecular testing.

YTD Price Performance: -6.10%

Average Trading Volume: 3,824,643

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £131M

See more data about HVO stock on TipRanks’ Stock Analysis page.